Medical News

RSS

IRIDEX commences commercial shipment of IQ 532 laser systems

IRIDEX Corporation, today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.

30 Apr 2010

First Edition: April 30, 2010

Today's headlines focus on state decisions regarding new health insurance pools; insurers' plans regarding the early adoption of some reform law provisions; and, of course, the politics that continue to surround health reform.

30 Apr 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

ISTA Pharmaceuticals, Inc., today reported financial results for the quarter ended March 31, 2010. First quarter 2010 net revenues were $28.3 million, an increase of 39% from the first quarter of 2009. Net income for the first quarter ended March 31, 2010, was $0.5 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.59 per share, for the first quarter ended March 31, 2009.

30 Apr 2010

MEDSEEK to enhance online experience for UNC Health Care patients

MEDSEEK, the industry's only provider of the eHealth ecoSystem, today announced its engagement to enhance the online experience for UNC Health Care patients.

30 Apr 2010

Researchers identify new genetic link to systemic scleroderma

An international research consortium including scientists from The University of Texas Health Science Center at Houston (UTHealth) has identified a new genetic link to the systemic form of scleroderma. Researchers believe a thorough understanding of the genetic nature of the disease is crucial to developing a cure.

30 Apr 2010

Opinions: Sanitation and women, child health; GM in Global Food Security bill; U.S. malaria strategy; GHI on NTDs; Haiti recovery

"If Stephen Harper is serious about maternal health and child health [as suggested by his plans for the upcoming G8 and G20 summits], he needs to recognize that healthy mothers come from healthy communities," Maude Barlow and Meera Karunananthan of the Council of Canadians write in a Chronicle Herald opinion piece that examines the connections between the health of women and children and access to drinking water and sanitation.

30 Apr 2010

pSivida announces presentations on bioerodible technologies for degenerative eye disease

pSivida Corp., a leader in the development of back of the eye drug delivery systems, today announced that two poster presentations will be made at the upcoming ARVO meeting on one of pSivida's next generation bioerodible technologies for degenerative eye disease. It marks a key step toward the ability to use pSivida's bioerodible technologies to develop treatments for glaucoma and other degenerative eye diseases, diseases that affect millions of Americans.

30 Apr 2010

Self-sealing sleeve for wound protection

As the days get longer and temperatures rise, so do incidences of outdoor-related injuries.

30 Apr 2010

MicroStockProfit.com releases investment report featuring Cardium Therapeutics

MicroStockProfit.com announces an investment report featuring Cardium Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

30 Apr 2010

BioScrip reports net loss of $7.2M on revenues of $335.1M for first-quarter 2010

BioScrip, Inc. today announced a first quarter net loss of $7.2 million, or $0.18 per share on revenues of $335.1 million. These results compare to net income of $3.3 million, or $0.08 per share, on revenues of $325.7 million for the first quarter of 2009.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.

30 Apr 2010

Whole-genome analysis may play future role in clinical medicine: Study

Scientists at Stanford and Harvard Universities collaborated to assess the clinical usefulness of analyzing a patient's full genome for disease risks and unusual drug responses. The work brings closer to reality the concept that whole-genome sequencing might one day play a clinical role.

30 Apr 2010

Magellan Health Services reports net revenue of $728.1M for first-quarter ended March 31, 2010

Magellan Health Services, Inc. today reported net revenue of $728.1 million, net income of $25.5 million or $0.73 per diluted common share, and segment profit, representing income from continuing operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes, of $61.4 million for the quarter ended March 31, 2010.

30 Apr 2010

NLV Partners closes second tranche of $26 million Series D financing in Oxford Immunotec

New Leaf Venture Partners (NLV Partners) announced today the closing of the second tranche of a $26 million investment in Oxford Immunotec Ltd., a leading manufacturer and marketer of T cell-based diagnostic tests. The Series D financing was led by NLV Partners, and additional participants included new investor Kaiser Permanente Ventures and existing investors Clarus Ventures, Wellington Partners, Kuwait-based National Technology Enterprises Company, SPARK Ventures, DFJ Esprit, Oxford University and The Dow Chemical Company.

30 Apr 2010

New PCA-Rx therapy provides natural toxin removal treatment to Alzheimer's patients

According to the Alzheimer's Association, over 5 million Americans are afflicted with Alzheimer's disease. While its cause is controversial, many people believe a correlation exists with toxin accumulation. Until recently, chelation, an invasive, drug-based toxin removal therapy, has been patients' primary option.

30 Apr 2010

Coventry Health Care reports net earnings of $97.3 million for first-quarter 2010

Coventry Health Care, Inc. today reported consolidated operating results for the quarter ended March 31, 2010. Operating revenues totaled $2.9 billion for the quarter with net earnings of $97.3 million, or $0.66 earnings per diluted share (EPS). Excluding the favorable impact of Medicare Advantage Private Fee-for-Service (MA-PFFS) results in the quarter, operating revenues totaled $2.9 billion for the quarter with net earnings of $71.9 million, or $0.49 EPS.

30 Apr 2010

Medical News

IRIDEX commences commercial shipment of IQ 532 laser systems

First Edition: April 30, 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

MEDSEEK to enhance online experience for UNC Health Care patients

Researchers identify new genetic link to systemic scleroderma

Opinions: Sanitation and women, child health; GM in Global Food Security bill; U.S. malaria strategy; GHI on NTDs; Haiti recovery

pSivida announces presentations on bioerodible technologies for degenerative eye disease

Self-sealing sleeve for wound protection

MicroStockProfit.com releases investment report featuring Cardium Therapeutics

BioScrip reports net loss of $7.2M on revenues of $335.1M for first-quarter 2010

REGN reports net loss of $30.5M for first-quarter 2010

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Whole-genome analysis may play future role in clinical medicine: Study

Magellan Health Services reports net revenue of $728.1M for first-quarter ended March 31, 2010

NLV Partners closes second tranche of $26 million Series D financing in Oxford Immunotec

New PCA-Rx therapy provides natural toxin removal treatment to Alzheimer's patients

Coventry Health Care reports net earnings of $97.3 million for first-quarter 2010

Amerigroup reports net income of $42.2M for first-quarter 2010

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Accurate reporting of errors can reduce preventable hospital deaths: SIOP

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News